Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

Jellinger KA, Korczyn AD. · 2018

Read Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? by Jellinger KA, Korczyn AD. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5840831.txt.

Introduction

Jellinger and Korczyn ask whether two Lewy body dementias are really one disease. Their review appeared in BMC Medicine. Dementia with Lewy bodies and Parkinson's disease dementia share symptoms, chemistry, and brain pathology. Clinicians split them only by which trouble comes first.

If thinking fails before or within a year of movement signs, the label is Lewy body dementia. Later decline in known Parkinson's earns the other label. The review finds heavier cortical amyloid and tau in the first group. Yet the two blend across a spectrum of synuclein disease. The authors lean toward one continuum with two extreme ends.

Catalog record

CREATORJellinger KA, Korczyn AD.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE107 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5840831

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? By Kurt A Jellinger, Amos D Korczyn Published in: BMC Medicine DOI: 10.1186/s12916-018-1016-8 ABSTRACT Abstract Background Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), which share many clinical, neurochemical, and morphological features, have been incorporated into DSM-5 as two separate entities of major neurocognitive disorders with Lewy bodies. Despite clinical overlap, their diagnosis is based on an arbitrary distinction concerning the time of onset of motor and cognitive symptoms, namely as early cognitive impairment in DLB and later onset following that of motor symptoms in PDD. Their morphological hallmarks – cortical and subcortical α-synuclein/Lewy body plus β-amyloid and tau pathologies – are similar, but clinical differences at onset suggest some dissimilar profiles. Based on recent publications, including the fourth consensus report of the DLB Consortium, a critical overview is provided herein. Discussion The clinical constellations of DLB and PDD include cognitive impairment, parkinsonism, visual hallucinations, and fluctuating attention. Intravitam PET and postmortem studies have revealed a more pronounced cortical atrophy, elevated cortical and limbic Lewy body pathologies, higher Aβ and tau loads in cortex and striatum in DLB compared to PDD, and earlier cognitive defects in DLB. Conversely, multitracer PET studies have shown no differences in cortical and striatal cholinergic and dopaminergic deficits. Clinical management of both DLB and PDD includes cholinesterase inhibitors and other pharmacologic and non-drug strategies, yet with only mild symptomatic effects. Currently, no disease-modifying therapies are available. Conclusion DLB and PDD are important dementia syndromes that overlap in many clinical features, genetics, neuropathology, and management. They are currently considered as subtypes of an α-synuclein-associated disease spectrum (Lewy body diseases), from incidental Lewy body disease and non-demented Parkinson’s disease to PDD, DLB, and DLB with Alzheimer’s disease at the most severe end. Cognitive impairment in these disorders is induced not only by α-synuclein-related neurodegeneration but by multiple regional pathological scores. Both DLB and PDD show heterogeneous pathology and neurochemistry, suggesting that they share important common underlying molecular pathogenesis with Alzheimer’s disease and other proteinopathies. While we prefer to view DLB and PDD as extremes on a continuum, there remains a pressing need to more clearly differentiate these syndromes and to understand the synucleinopathy processes leading to either one. Keywords: Dementia with Lewy bodies, Parkinson’s disease dementia, Clinical features, Diagnostic criteria, Neuropathology, Diagnostic tests, Management, Synucleinopathies BACKGROUND The nosologic relationship, as defined by DSM-5 [1, 2], between dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), both of which are major neurocognitive disorders with α-synuclein (αSyn) deposition/Lewy bodies (LB), is continuously being debated [3–22]. The clinical features of DLB and PDD are similar and include dementia, cognitive fluctuations, and (visual) hallucinations in the setting of clinical or latent parkinsonism. The cognitive domains of both disorders overlap, with progressive executive dysfunctions, visual-spatial abnormalities, and memory disorders [10]. Based on international consensus, DLB is diagnosed when cognitive impairment precedes parkinsonian motor signs or begins within 1 year from its onset [23], whereas in PDD, cognitive impairment develops in the setting of well-established Parkinson’s disease (PD) [24]. DLB patients will also develop parkinsonism of increasing severity over the years, although 25% of them never develop parkinsonian symptoms [25]. Despite different temporal sequences of motor and cognitive deficits and several quantitative clinical differences, both disorders show largely convergent, albeit locally and quantitatively divergent neuropathological lesions, associated with increased Aβ and tau loads in DLB [9, 26–30]. The overlap of clinical and morphological features has led to the debate of whether DLB and PDD are the same disease [17], different phenotypic expressions of the same αSyn/Lewy body disease (LBD) spectrum, or distinct ‘diseases’ [3, 31] sharing genetic risk features with PD and Alzheimer’s disease (AD) [10, 32], despite recent studies indicating a regional overlap of pathologies [33–37]. The present paper will critically review the major current findings in DLB and PDD, their possible nosologic interrelations, and the available biological markers and therapies. Of note, this review does not include mild cognitive impairment in LBD (see [8, 38–46]). Clinical features and diagnostic criteria of DLB The presenting features of DLB can be broadly placed into three categories, namely cognitive impairment, behavioral/psychiatric phenomena, and physical symptoms [47]. Essential for its diagnosis are dementia with moderate memory impairment, deficits in attention, executive dysfunction and visuoperceptual ability, fluctuating cognition (presumably related to thalamic damage and cholinergic imbalance [48]), and recurrent visual hallucinations that are well formed and detailed [2]. Hallucinations in DLB may occur spontaneously, independent of visuospatial and perceptional impairment [49], and possibly related to LBs in the temporal lobe [50], while in PDD they typically occur after dopaminergic therapy [10, 23, 51]. Nevertheless, hallucinations had been reported prior to the levodopa era [52] as well as in drug-naive PD patients even in the premotor phase [53]. Language impairment tends to be mild, with verbal and semantic fluency deficits. Spontaneous parkinsonian features, such as bradykinesia and rigidity, are common in DLB (over 85%) [31], while rest tremor is less frequent [54]. REM sleep behavior disorder (RBD), which shows a high prevalence in DLB and may precede cognitive decline by decades, is now included as a core clinical feature [55]. RBD may reflect a distinct subtype of DLB with earlier disease onset [56], associated with severe brain metabolic decreases [57]; however, as an early manifestation, it is not specific to DLB [58, 59]. The pattern of initial cognitive dysfunction differs between DLB and PDD [60], with greater deficiencies of attention, executive function, and constructive abilities, as well as significantly lower ratings in episodic verbal memory tasks, in DLB [61, 62]. Further, the rate of cognitive decline is reportedly faster in DLB than in PDD and AD [63, 64] (Table 1). [Table: Clinical overlap and dissimilarities between dementia with Lewy bodies (DLB) and Parkinson disease with dementia (PDD)] Supporting clinical features for the diagnosis of probable or possible DLB are repeated falls, syncopes, hyposmia, severe autonomic dysfunction, hypersomnia, hallucinations in non-visual modalities, apathy, depression, and severe sensitivity to antipsychotic agents [2, 65]. However, since these changes also occur in advanced PD, they cannot differentiate DLB from PDD, e.g., the prevalence of neuroleptic sensitivity does not differ significantly between them [66]. A diagnosis of clinically probable DLB requires (1) two or more core clinical features to be present, with or without indicative biomarkers, or (2) the presence of only one core clinical feature but with one or more indicative biomarkers [2]. Although the diagnostic specificity of these criteria is high (range 79–100%), the sensitivity can be low (12–88%), improving with additional supporting features such as biomarkers [67–70]. A recent meta-analysis reported a pooled sensitivity, specificity, and accuracy of 60.2% (95% CI 30.9–83.7%), 93.8% (83.8–97.6%), and 79.7% (62.6–90.7%), respectively, for the diagnostic [23] criteria of DLB [68]. Thus, currently, approximately 20% of DLB diagnoses are incorrect [68, 69]. Clinical features and diagnostic guidelines of PDD The clinical features of PDD are in many respects similar to those seen in DLB, although, by definition [23, 71], the occurrence of parkinsonism distinguishes one from the other. Rigidity and akinesia occur both in PDD and DLB [62]. Cognitive impairments in PDD are common and are similar in quality to those of DLB [8]. However, the timing, profile, and

Read the complete text